Silvio Edward Inzucchi MD

Adrenal Disease, Diabetes, Pituitary Disorders & Neuroendocrinology

Professor of Medicine, Yale University

789 Howard Avenue 2nd FloorDana BuildingNew Haven, CT 06510

Dr. Inzucchi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Inzucchi's full profile Already have an account?

Education & Training

Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
Harvard Medical SchoolClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Publications & Presentations

PubMed

Sodium Glucose Cotransporter-2 Inhibitors are Not Associated with Amputation After Lower Extremity Revascularization in Patients with Diabetes.
Uma D Alappan, Ashwin K Chetty, Warren Carter, Nicholas Wells, Dana Alameddine
Annals of Vascular Surgery. 2026-09-01
Dapagliflozin in Patients With Heart Failure Across the Care Spectrum: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68.
David D Berg, Muthiah Vaduganathan, Kieran F Docherty, Andrea Bellavia, Sabina A Murphy
JACC. Heart Failure. 2026-08-01
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
Silvio E Inzucchi, Rohana Abdul Ghani, John Deanfield, Scott Emerson, Mads D M Engelmann
The Journal of Clinical Endocrinology and Metabolism. 2026-07-21

Journal Articles

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Silvio Inzucchi, MD, Journal of the American Society of Nephrology
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Christina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine

Lectures

Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers
American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers
Scientific Sessions 2008, New Orleans, Louisiana, USA
Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers
Scientific Sessions 2010, Chicago, Illinois, USA

Other

Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers
Silvio Inzucchi, MD, Diabetes, Obesity and Metabolism
https://www.doximity.com/articles/b552b1a0-ea89-475a-8388-913374468095
UpToDate, Wolters Kluwer Health - 2012-07-30
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Silvio Inzucchi, MD, Annals of Internal Medicine
https://www.doximity.com/articles/dea6d159-a396-4c8a-8d46-4b009fecfb26
UpToDate, Wolters Kluwer Health - 2012-05-24

Press Mentions

The GLP-1 RevolutionDecember 1st, 2025
SOUL Trial Shows Oral Semaglutide Has Positive CV Benefits in Type 2 DiabetesJune 23rd, 2025
Medscape InDiscussion: Type 2 DiabetesJuly 12th, 2022

Grant Support

GRADE TrialNIDDK2013–2020
Dosage According To IGF1 Response In Growth Hormone DefiNational Center For Research Resources2000–2001
Effects Of Troglitazone And Metformin On Glucose MetabolismNational Center For Research Resources1996–1999
Ovine CRH In Evaluation Of Cushing SyndromeNational Center For Research Resources1997
Endocrine Evaluation Of Patients With Diseases Of The PituitaryNational Center For Research Resources1996–1997